Remove category state-and-federal-regulatory-issues
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

The products found, subject to retention and seizure, were retained by the Federal Revenue Service. The products had been improperly regularized in ANVISA as cosmetics since they are indicated for injectable use, a form that is not authorized for this category of product. and Biometik Indústria e Comércio de Cosméticos.

FDA 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

SQA Regulatory Surveillance Summary for September and October 2022. This guidance will help applicants interpret how to implement Essential Principles of Medical Device Safety and Performance using information that was issued in March 2020. Agência Nacional de Vigilância Sanitária (ANVISA). CMDE Announcement No. CMDE Announcement No.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

From 01 December 2022, all provincial-level drug regulatory authorities shall issue the Certificate of a Pharmaceutical Product in accordance with the new template. The electronic certificate and the paper version are equally authentic. Efforts should be made to promote and guide the use of electronic certificates.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – March And April

SQA

The objective is to reinforce actions for the prevention and control of diseases such as dengue and chikungunya, arboviruses transmitted by the Aedes aegypti mosquito. For this, it is necessary to maintain regular active surveillance and vector control so that the risk of disease transmission is reduced.

FDA 40
article thumbnail

CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule

Healthcare Law Blog

The Proposed Rule covers an array of regulatory topics including the Star Ratings program, marketing and communications, agent and broker compensation, health equity, dual eligible special needs plans (“D-SNPs”), utilization management, network adequacy, and access to biosimilars. Below is a summary of some of the Proposed Rule’s key changes.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – July/August

SQA

SQA Regulatory Surveillance Summary for July and August 2022. The counterfeit devices were sold online by a distributor named Healthful Plus without the required license to import, distribute, or sell medical devices in Canada. The packaging of the counterfeit kits resembles authentic (licensed) BTNX Inc. Health Canada.